Miami Cancer Institute expects to be the primary destination for cancer patients in the southeastern United States, Latin America and the Caribbean. The center provides all cancer services under one roof. Besides the proton facility, Miami Cancer Institute hosts other front-line treatment modalities from Accuray, Elekta, Varian and ViewRay. The customer has chosen C-RAD’s SGRT (Surface Image Guided Radiation Therapy) solution to optimize patient safety before and during treatment. Due to the precision of proton therapy in delivering radiation dose to the tumor, a high level of accuracy is required for patient positioning before and during treatment.
The Catalyst™ system will be delivered with the complete software suite with modules for Respiratory Gating, Patient Setup and Positioning and Motion Monitoring. The C-RAD SGRT solution provides a continuous monitoring of the patient during a treatment fraction. Patient motion above a clinically defined threshold will interrupt the treatment beam.
C-RAD provides interfaces to seamlessly integrate its products into the workflow. In April 2015, C-RAD validated its respiratory gating interface for IBA proton and particle therapy. It is the intention to cooperate with Miami Cancer Institute to develop a dedicated clinical workflow for proton therapy.
C-RAD Sentinel 4DCT is an easy-to-use, laser-based optical surface scanning system with functionality for 4D CT reconstruction and gated imaging in a CT room. It also provides reference images for patient positioning.
Alonso N. Gutierrez, PhD, MBA, Chief of Medical Physics, from Miami Cancer Institute says:
“We are excited to welcome this technology to our state-of-the-art proton center. Using the Catalyst HD system, we believe we will be able to improve our initial patient set up, monitor any patient motion during beam-on and gate the proton beam in an efficient manner to facilitate patient throughput.”
“We are honored to work with the team from Miami Cancer Institute on this prestigious project. It is our intention to build-up this site as an international reference site in the proton therapy landscape.” says Tim Thurn, CEO and President of C-RAD AB, “The overall development within radiation therapy is encouraging for C-RAD. The demand for accurate patient positioning is continuously increasing, and I am confident that C-RAD will contribute to help cure more cancer patients with our cutting-edge solutions and as being a trusted partner to our customers.”
The order amounts to a total of approximately 7,5 mSEK and includes the delivery of the systems and a service contract for a period of five years. Ít is expected to commence delivery and installation in the second quarter 2017. The project is booked as order intake in the second quarter 2017.
About Baptist Health South Florida
Baptist Health is the largest healthcare organization in South Florida, with seven hospitals (Baptist Hospital, Baptist Children’s Hospital, Doctors Hospital, Homestead Hospital, Mariners Hospital, South Miami Hospital and West Kendall Baptist Hospital) and more than 30 outpatient and urgent care facilities spanning three counties. Not-for-profit, faith-based Baptist Health has more than 15,000 employees and 2,200 affiliated physicians, and also includes Baptist Heath Medical Group, Baptist Outpatient Services and internationally renowned centers of excellence.
Baptist Health Foundation, the organization’s fundraising arm, supports services at all hospitals and facilities. Baptist Health is listed by Fortune magazine as one of the 100 Best Companies to Work for in America (No. 23 in the nation) and has remained on the list for 15 years. It is also recognized as one of the World’s Most Ethical Companies for the fifth year in a row by Ethisphere Institute.
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit https://www.c-rad.com
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email email@example.com
This information is information that C-RAD AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 08:30 CET on April 18, 2017.